Phase 1 N=16 Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)
Hypertension
Primary: Number of Participants With Adverse Events (AEs) — 4; 4; 3; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Phase 1 N=328 The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers
ECG Effects
Primary: The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)…
Phase 1 N=37 Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Systemic Lupus Erythematosus
Primary: Frequency of Participants With Adverse Events — 21; 33 Participants
Phase 1 N=10 Phase I Study of Nicotinamide for Early Onset Preeclampsia
Pregnancy Induced Hypertension · Superimposed Preeclampsia · Hypertension
Primary: Number of Participants With Adverse Events — 2; 0 participants
Phase 1 N=15 Pharmacokinetics of Leptin Administration During Fasting
Energy Deficiency Due to Short-term Fasting
Primary: Leptin Pharmacokinetic Parameters - TIME(T1/2) DAY 3 / TMAX DAY 3 72-hour Fasting Day 3 Leptin Dose 0.01 mg/kg — 1.93; 2.75; 2.99; 2.00 HR
Phase 1 N=33 Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM) — 173.8; 152.2 mg/dL — p=0.0118
Phase 1 N=78 Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Neoplasms
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 4; 4; 4; 4 Participants
Phase 1 N=36 A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects
Hypertension
Primary: Area Under the Concentration-time Curve — 690.43; 820.86; 86.442; 114.55 ng*hr/mL
Phase 1 N=30 A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.
Healthy
Primary: Mean Plasma Concentration (AUC) of Cyclobenzaprine — 47,074.19; 94,874.26; 50,263.16 pg.hr/mL
Phase 1 N=41 Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 4; 4; 6 participants
Phase 1 N=117 PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
Diabetes Mellitus, Type 2
Primary: Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A — 2; 2; 1; 1 participants
Phase 1 N=54 First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
Healthy Subjects
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 participants
Phase 1 N=24 A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
Diabetes Mellitus, Type 2
Primary: Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value) — 59.09; 55.52; 17.22; 19.67 milligram*hour per deciliter
Phase 1 N=36 Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks
Marijuana Use Disorder
Primary: Change From Baseline in Iowa Gambling Task Scores [Objective Measure of Decision Making] — 3.7; 10.1; 4.4 mean number of cards